• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Bangalore, Sept. 4

Strides Arcolab Ltd said it has received ANDA approvals from the USFDA for two dexamethasone products, taking its tally to 11 out of 18 filings. The latest approvals are for anti-inflammatory injections dexamethasone USP, 4mg/ml, (1ml single-dose vials, 20mg /5 ml, 120 mg /30 ml multiple dose vials) and dexamethasone sodium phosphate USP, 10 mg /ml, (10 ml multiple-dose vials). The products are licensed to Akorn-Strides, LLC, the joint venture formed in 2004 with Akorn Inc . Mr Ravi Seth, CEO - International Operations, Strides, said, “The Akorn-Strides partnership has now received 11 ANDA approvals of the 18 filed till date and commercialisation of some of these products has already commenced effective Q3, 2008.”

—Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line